SCHEMBL22819395

SCHEMBL22819395

CCCC[C@H](COC(=O)C(C)C)Nc1nc(NC(=O)C(C)C)nc2c(C)cccc12

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KCNH2 Q12809 3/20 0.39
▸ ATM Q13315 1/20 0.39
▸ CTNNB1 P35222 4/20 0.39
▸ TCF7L2 Q9NQB0 4/20 0.39
▸ KDM4E B2RXH2 2/20 0.37
▸ CASP1 P29466 2/20 0.37
▸ CASP7 P55210 2/20 0.37
▸ MAPT P10636 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ TLR8 Q9NR97 4/20 0.36
▸ TLR7 Q9NYK1 3/20 0.36
▸ RPS6KB1 P23443 1/20 0.36
▸ NOS1 P29475 1/20 0.35
▸ ELANE P08246 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29601605 1.00 KCNH2 (0.39) KCNH2ATMCTNNB1TCF7L2KDM4E
SCHEMBL24384569 0.86 KCNH2 (0.55) KCNH2TLR8TLR7CYP2D6
SCHEMBL22959029 0.86 KCNH2 (0.55) KCNH2TLR8TLR7CYP2D6
SCHEMBL29601645 0.80 TLR8 (0.47) KCNH2CTNNB1TCF7L2KDM4ETLR8
SCHEMBL22819485 0.80 TLR8 (0.47) KCNH2CTNNB1TCF7L2KDM4ETLR8
SCHEMBL22958983 0.77 KCNH2 (0.56) KCNH2TLR8TLR7CYP2D6
SCHEMBL28698017 0.75 ATM (0.38) ATMCTNNB1TCF7L2KDM4ECASP1
SCHEMBL28701677 0.70 TLR8 (0.51) KCNH2TLR8TLR7RPS6KB1CYP2D6
SCHEMBL28701678 0.70 TLR8 (0.51) KCNH2TLR8TLR7RPS6KB1CYP2D6
SCHEMBL24719004 0.69 TLR8 (0.69) KCNH2TLR8TLR7CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3986871-B1 QUINAZOLINE PRODRUGS FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) 2023-06-07 — — EP disclosed
WO-2020254473-A1 QUINAZOLINE PRODRUGS FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES Janssen Sciences Ireland Unlimited Company (IE) 2020-12-24 — — WO disclosed
WO-2020255019-A1 COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND A QUINAZOLINE DERIVATIVE Janssen Sciences Ireland Unlimited Company (IE) 2020-12-24 — — WO disclosed
Send feedback